- id: rule_genetics_warfarin_pharmacogenomics
  name: Warfarin Pharmacogenomic Testing
  description: Prior authorization for CYP2C9 and VKORC1 testing to guide warfarin dosing
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - '81355' # VKORC1 (vitamin K epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variant(s)
          - '81227' # CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants
          - '81230' # CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant
      - diagnosis_code:
          any_of:
          - I48.91  # Unspecified atrial fibrillation
          - I26.99  # Other pulmonary embolism without acute cor pulmonale
          - I82.401 # Acute embolism and thrombosis of unspecified deep veins of right lower extremity
          - I82.402 # Acute embolism and thrombosis of unspecified deep veins of left lower extremity
          - Z51.81  # Encounter for therapeutic drug level monitoring
          - Z79.01  # Long term (current) use of anticoagulants
      - patient_age:
          min: 18
      - any_of:
        - all_of:
          - diagnosis_code:
              any_of:
              - I48.91 # Atrial fibrillation requiring anticoagulation
          - prior_service_within_days:
              service_codes:
              - '93000' # ECG confirming atrial fibrillation
              - '93005'
              days: 180
              description: ECG documentation within past 6 months
          - prior_service_within_days:
              service_codes:
              - '99213' # Initiation of warfarin therapy
              - '99214'
              - '99215'
              days: 30
              description: Warfarin initiation within past 30 days
        - all_of:
          - diagnosis_code:
              any_of:
              - I26.99 # Pulmonary embolism
              - I82.401 # Deep vein thrombosis
              - I82.402
          - prior_service_within_days:
              service_codes:
              - '71275' # CTA or V/Q scan confirming VTE
              - '78580'
              days: 90
              description: VTE imaging within past 90 days
        - all_of:
          - diagnosis_code:
              any_of:
              - Z51.81 # Difficult warfarin dosing
          - prior_service_within_days:
              service_codes:
              - '85610' # Multiple INR values outside therapeutic range
              days: 90
              description: Unstable INR within past 90 days
      - prior_service_within_days:
          service_codes:
          - '99213' # Cardiology or hematology evaluation
          - '99214'
          - '99215'
          days: 90
          description: Specialist consultation within past 90 days
      - none_of:
        - prior_service_within_days:
            service_codes:
            - '81355' # Previous warfarin pharmacogenomic testing
            - '81227'
            days: 1825
            description: Warfarin PGx testing within past 5 years
        - diagnosis_code:
            any_of:
            - Z87.891 # History of nicotine dependence (may affect metabolism)
  logic:
    outcome: approved
    reason: Warfarin pharmacogenomic testing approved for anticoagulation initiation or dosing difficulties
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: CYP2C9 and VKORC1 variants significantly affect warfarin dosing requirements

- id: rule_genetics_clopidogrel_pharmacogenomics
  name: Clopidogrel Pharmacogenomic Testing
  description: Prior authorization for CYP2C19 testing to guide clopidogrel therapy
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - '81225' # CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants
      - diagnosis_code:
          any_of:
          - I21.9   # Acute myocardial infarction, unspecified
          - I25.10  # Atherosclerotic heart disease of native coronary artery without angina pectoris
          - Z95.1   # Presence of aortocoronary bypass graft
          - Z95.5   # Presence of coronary angioplasty implant and graft
          - I63.9   # Cerebral infarction, unspecified
      - patient_age:
          min: 18
      - any_of:
        - all_of:
          - diagnosis_code:
              any_of:
              - I21.9  # Acute coronary syndrome
          - prior_service_within_days:
              service_codes:
              - '93000' # ECG showing acute changes
              - '93005'
              days: 30
              description: Acute ECG changes within past 30 days
          - prior_service_within_days:
              service_codes:
              - '82550' # Elevated cardiac enzymes
              days: 30
              description: Cardiac biomarkers within past 30 days
        - all_of:
          - diagnosis_code:
              any_of:
              - Z95.5  # Post-PCI with stent placement
          - prior_service_within_days:
              service_codes:
              - '92928' # Percutaneous coronary intervention
              - '92933'
              - '92937'
              days: 30
              description: PCI within past 30 days
        - all_of:
          - diagnosis_code:
              any_of:
              - I63.9  # Ischemic stroke
          - prior_service_within_days:
              service_codes:
              - '70450' # CT or MRI showing acute stroke
              - '70551'
              - '70552'
              days: 90
              description: Stroke imaging within past 90 days
        - all_of:
          - prior_service_within_days:
              service_codes:
              - '99213' # High bleeding risk or recurrent events on clopidogrel
              - '99214'
              - '99215'
              days: 90
              description: Clopidogrel failure evaluation within past 90 days
      - prior_service_within_days:
          service_codes:
          - '99213' # Cardiology evaluation
          - '99214'
          - '99215'
          days: 90
          description: Cardiology consultation within past 90 days
      - none_of:
        - prior_service_within_days:
            service_codes:
            - '81225' # Previous CYP2C19 testing
            days: 1825
            description: CYP2C19 testing within past 5 years
  logic:
    outcome: approved
    reason: CYP2C19 testing approved for clopidogrel therapy optimization in cardiovascular disease
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: CYP2C19 poor metabolizers have reduced clopidogrel efficacy and increased cardiovascular events

- id: rule_genetics_psychiatric_pharmacogenomics
  name: Psychiatric Pharmacogenomic Testing
  description: Prior authorization for pharmacogenomic testing to guide psychiatric medication selection
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - '0175U' # Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 14 genes
          - '0073U' # CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants
          - '81226' # CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants
      - diagnosis_code:
          any_of:
          - F32.9   # Major depressive disorder, single episode, unspecified
          - F33.9   # Major depressive disorder, recurrent, unspecified
          - F41.1   # Generalized anxiety disorder
          - F31.9   # Bipolar disorder, unspecified
          - F25.9   # Schizoaffective disorder, unspecified
          - F20.9   # Schizophrenia, unspecified
      - patient_age:
          min: 18
      - any_of:
        - all_of:
          - diagnosis_code:
              any_of:
              - F32.9  # Treatment-resistant depression
              - F33.9
          - prior_service_within_days:
              service_codes:
              - '99213' # Failed â‰¥2 antidepressant trials
              - '99214'
              - '99215'
              days: 365
              description: Multiple antidepressant failures within past year
        - all_of:
          - diagnosis_code:
              any_of:
              - F31.9  # Bipolar disorder
          - prior_service_within_days:
              service_codes:
              - '99213' # Medication intolerance or poor response
              - '99214'
              - '99215'
              days: 180
              description: Mood stabilizer issues within past 6 months
        - all_of:
          - diagnosis_code:
              any_of:
              - F20.9  # Schizophrenia
              - F25.9  # Schizoaffective disorder
          - prior_service_within_days:
              service_codes:
              - '99213' # Antipsychotic side effects or poor response
              - '99214'
              - '99215'
              days: 180
              description: Antipsychotic optimization within past 6 months
        - all_of:
          - patient_age:
              min: 65  # Elderly patients at higher risk for drug interactions
          - diagnosis_code:
              any_of:
              - F32.9  # Depression in elderly
              - F33.9
      - prior_service_within_days:
          service_codes:
          - '99213' # Psychiatry evaluation
          - '99214'
          - '99215'
          days: 90
          description: Psychiatric consultation within past 90 days
      - none_of:
        - prior_service_within_days:
            service_codes:
            - '0175U' # Previous psychiatric pharmacogenomic testing
            - '0073U'
            - '81226'
            days: 1825
            description: Psychiatric PGx testing within past 5 years
  logic:
    outcome: approved
    reason: Psychiatric pharmacogenomic testing approved for treatment-resistant conditions or medication optimization
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: Pharmacogenomic testing guides psychiatric medication selection and reduces adverse effects

- id: rule_genetics_oncology_pharmacogenomics
  name: Oncology Pharmacogenomic Testing
  description: Prior authorization for pharmacogenomic testing to guide chemotherapy dosing
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - '81232' # DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, common variant(s)
          - '81234' # DYPD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, full sequence analysis
          - '81350' # UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, irinotecan metabolism), gene analysis, common variant(s)
      - diagnosis_code:
          any_of:
          - C18.9   # Malignant neoplasm of colon, unspecified
          - C20     # Malignant neoplasm of rectum
          - C25.9   # Malignant neoplasm of pancreas, unspecified
          - C50.911 # Malignant neoplasm of unspecified site of right female breast
          - C78.5   # Secondary malignant neoplasm of large intestine and rectum
      - patient_age:
          min: 18
      - any_of:
        - all_of:
          - diagnosis_code:
              any_of:
              - C18.9  # Colorectal cancer planned for 5-FU/capecitabine
              - C20
              - C78.5
          - prior_service_within_days:
              service_codes:
              - '88305' # Tissue diagnosis confirming colorectal adenocarcinoma
              days: 180
              description: Tissue diagnosis within past 6 months
          - prior_service_within_days:
              service_codes:
              - '99213' # Planned 5-FU or capecitabine therapy
              - '99214'
              - '99215'
              days: 30
              description: Chemotherapy planning within past 30 days
        - all_of:
          - diagnosis_code:
              any_of:
              - C18.9  # Colorectal cancer planned for irinotecan
              - C20
              - C78.5
          - prior_service_within_days:
              service_codes:
              - '99213' # Planned irinotecan-based therapy
              - '99214'
              - '99215'
              days: 30
              description: Irinotecan planning within past 30 days
        - all_of:
          - diagnosis_code:
              any_of:
              - C25.9  # Pancreatic cancer planned for 5-FU
          - prior_service_within_days:
              service_codes:
              - '88305' # Tissue diagnosis confirming pancreatic adenocarcinoma
              days: 180
              description: Tissue diagnosis within past 6 months
        - all_of:
          - diagnosis_code:
              any_of:
              - C50.911 # Breast cancer planned for 5-FU
              - C50.912
          - prior_service_within_days:
              service_codes:
              - '99213' # Planned 5-FU-based adjuvant therapy
              - '99214'
              - '99215'
              days: 30
              description: Adjuvant chemotherapy planning within past 30 days
      - prior_service_within_days:
          service_codes:
          - '99213' # Oncology evaluation
          - '99214'
          - '99215'
          days: 90
          description: Oncology consultation within past 90 days
      - none_of:
        - prior_service_within_days:
            service_codes:
            - '81232' # Previous DPYD or UGT1A1 testing
            - '81234'
            - '81350'
            days: 1825
            description: Oncology PGx testing within past 5 years
  logic:
    outcome: approved
    reason: Oncology pharmacogenomic testing approved to prevent severe chemotherapy toxicity
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: DPYD and UGT1A1 deficiency can cause life-threatening chemotherapy toxicity

- id: rule_genetics_pain_management_pharmacogenomics
  name: Pain Management Pharmacogenomic Testing
  description: Prior authorization for pharmacogenomic testing to guide opioid and pain medication selection
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - '0029U' # Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823)
          - '81226' # CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants
          - '0073U' # CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants
      - diagnosis_code:
          any_of:
          - M79.3   # Panniculitis, unspecified
          - G89.29  # Other chronic pain
          - M25.50  # Pain in unspecified joint
          - F11.10  # Opioid abuse, uncomplicated
          - Z87.891 # Personal history of nicotine dependence
      - patient_age:
          min: 18
      - any_of:
        - all_of:
          - diagnosis_code:
              any_of:
              - G89.29 # Chronic pain requiring opioid therapy
          - prior_service_within_days:
              service_codes:
              - '99213' # Failed multiple pain medications
              - '99214'
              - '99215'
              days: 180
              description: Multiple analgesic failures within past 6 months
        - all_of:
          - diagnosis_code:
              any_of:
              - F11.10 # Opioid use disorder
          - prior_service_within_days:
              service_codes:
              - '99213' # Medication-assisted treatment planning
              - '99214'
              - '99215'
              days: 90
              description: MAT evaluation within past 90 days
        - all_of:
          - prior_service_within_days:
              service_codes:
              - '99213' # Severe adverse effects to pain medications
              - '99214'
              - '99215'
              days: 90
              description: Medication intolerance within past 90 days
        - all_of:
          - patient_age:
              min: 65  # Elderly patients at higher risk
          - diagnosis_code:
              any_of:
              - G89.29 # Chronic pain in elderly
      - prior_service_within_days:
          service_codes:
          - '99213' # Pain management or addiction medicine evaluation
          - '99214'
          - '99215'
          days: 90
          description: Specialist consultation within past 90 days
      - none_of:
        - prior_service_within_days:
            service_codes:
            - '0029U' # Previous pain management pharmacogenomic testing
            - '81226'
            - '0073U'
            days: 1825
            description: Pain PGx testing within past 5 years
  logic:
    outcome: approved
    reason: Pain management pharmacogenomic testing approved for medication optimization or opioid use disorder treatment
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: Pharmacogenomic testing optimizes pain medication selection and reduces adverse effects
